Abstract:11574 Background: EHE is an ultra-rare sarcoma, showing a highly variable clinical behavior, from indolent to very aggressive. Systemic agents available for treatment of sarcoma have marginal activity in EHE. S showed antitumor effect in PDX models and pts affected by advanced EHE. However, clinical data on S in EHE are only retrospective and uncontrolled. This makes it difficult to interpret if the median progression-free survival (m-PFS) of 13 mos and the m-overall survival (m-OS) of 18.8 mos observed in the 38 progressive pts included in the largest series available (Stacchiotti et al, doi:10.1002/cncr.33247) were attributable to the antitumor effect of S or to EHE natural history. To fill this gap, we reviewed the outcome of pts included in this series who went off S. Methods: Clinical data of all EHE pts included in the above-mentioned retrospective study and treated with S for advanced disease between 2010 and 2019 were reviewed, focusing on pts who discontinued S for any reason. Progression was retrospectively categorized by RECIST 1.1 progressive disease (PD) and as “clinical progression” (CP), CP being defined as worsening of systemic symptoms and/or serosal effusion without criteria for RECIST PD. Survival analyses were performed by Kaplan-Meier method. OS was defined as the time from S start until death or last follow-up (FU), post-discontinuation OS (pOS) as the time from S discontinuation until death or last FU, post-discontinuation PFS (pPFS) as the time from S discontinuation until first evidence of progression (PD or CP) or death, post-re-challenge PFS (pR-PFS) as the time from S re-challenge until first evidence of progression (PD or CP) or death. Results: Of the 38 pts, 24 stopped S and were included in this analysis (median age = 47 yrs; serosal effusion yes/no = 9/15; S discontinuation due to: RECIST PD = 12, CP = 3, toxicity = 7; other = 2). After S discontinuation all pts had an event (PD or CP or death), and 13/24 (54%) pts did not receive further treatments, while 11/24 (46%) started again a systemic treatment. In particular, 6/24 (25%) restarted S (all after interval progression, PD or CP) with a new stable disease in 5/6 cases. At last FU, 6/24 (25%) pts were alive, 18/24 (75%) dead. At 62.2-mo m-FU (IQR 46-124), m-OS was 14.3 mos (95% CI, 7.3-21.2). Overall m-pPFS was 3.02 mos (95% CI, 1.6-4.4), m-pOS was 7.15 mos (95% CI, 4.4-9.9). m-pPFS of pts who discontinued S without evidence of progression (PD or CP) was also 3.02 mos (95% CI, 2.9-3.1). m-PFS following the re-challenge of S (m-pR-PFS) was unreached; 1 pt died following PD after 19 mos, 1 pt was alive and showed CP at 40 mos, 4 were alive and progression-free after 27, 31, 55, 94 mos. Conclusions: In our study the outcome of EHE pts who discontinued S was poor, with a m-pPFS of 3 mos and a m-pOS of 7 mos. However, pts who discontinued S for reasons other than progression benefited from S re-challenge, suggesting that in advanced EHE there is a subset of long-responders to S.

Outcome of patients (PTS) with advanced epithelioid hemangioendothelioma (EHE) after failure on sirolimus (S).

The patient perspective on sirolimus for epithelioid hemangioendothelioma (EHE): results of a community survey highlighting the importance of equitable access to treatments

Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature

Short-term outcomes of combined therapy with sirolimus and interferon-alpha 2b for advanced hepatic epithelioid hemangioendothelioma

GDF-15 predicts epithelioid hemangioendothelioma aggressiveness and is down-regulated by sirolimus through ATF4/ATF5 suppression

Sirolimus for the Treatment of Progressive Kaposiform Hemangioendothelioma: A Multicenter Retrospective Study

Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group

Management and Long‐Term Outcomes of Patients With Hepatic Epithelioid Hemangioendothelioma

Long-term outcomes of sequential chemotherapy in epithelioid sarcoma

Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy

Comprehensive Evaluation of Clinical Outcomes in Hepatic Epithelioid Hemangioendothelioma Subsets: Insights from SEER Database and Departmental Cohort Analysis

Clinical Characteristic and Prognosis of Epithelioid Hemangioendothelioma: 35 Cases from Single Center in Recent Decade

Favorable long term effects of intensified immunosuppression combined with therapeutic plasma exchange in patients with early-onset progressive systemic sclerosis-related interstitial lung disease

Efficacy of high dose chemotherapy in adult patients with relapsed or refractory ewing sarcoma

Sirolimus for the Treatment of Kaposiform Hemangioendothelioma: in a Trough Level-Dependent Way

Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update

Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment

International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms: Outcome of Primary Localized Disease

Systemic metastases from low-grade and high-grade pseudomyxoma peritonei: Treatments and outcomes

Endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma: long-term follow-up in a Western center

nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors